广东医学
廣東醫學
엄동의학
GUNAGDONG MEDICAL JOURNAL
2015年
6期
857-859,860
,共4页
刘民强%何俊永%王华%张沛沛%马明飞%李仁宰%何仁亮
劉民彊%何俊永%王華%張沛沛%馬明飛%李仁宰%何仁亮
류민강%하준영%왕화%장패패%마명비%리인재%하인량
性别%结核%顺式阿曲库铵%药效学
性彆%結覈%順式阿麯庫銨%藥效學
성별%결핵%순식아곡고안%약효학
gender%tuberculosis%cis-atracurium%pharmacodynamics
目的:探讨性别对结核病患者顺式阿曲库铵药效学参数的影响。方法择期行全身麻醉手术80例,结核病( T组)及非结核病( N组)患者40例,两组依性别不同分为结核病男性组( TM组)、女性组( TF组)及非结核病男性组( NM组)、女性组( NF组),每组20例。所有患者入室后予静脉输注咪达唑仑0.1 mg/kg、芬太尼4μg/kg,靶控输注丙泊酚1~4μg/mL,患者意识消失后采用4个成串刺激进行肌松监测,静脉注射顺式阿曲库铵0.15 mg/kg,当第1个肌颤搐反应( T1)下降至最低值并连续重复3次以上时行气管插管,记录起效时间、T1最大抑制程度、临床作用时间、恢复指数、药理作用时间及气管插管条件和麻醉诱导前(t0)、给予肌松药后5 min(t1)、15 min(t2)、30 min(t3)、45 min(t4)、1 h(t5)时的平均动脉压和心率。结果与男性相比,T组女性起效时间较短,临床作用时间及药理作用时间较长( P<0.01);与N组相比,T组患者顺式阿曲库铵临床作用时间及药理作用时间较短,但组间差异无统计学意义( P>0.05)。结论结核病患者顺式阿曲库铵单次静脉注射时女性较男性更敏感,表现为起效时间较短,临床作用时间及药理作用时间较长。
目的:探討性彆對結覈病患者順式阿麯庫銨藥效學參數的影響。方法擇期行全身痳醉手術80例,結覈病( T組)及非結覈病( N組)患者40例,兩組依性彆不同分為結覈病男性組( TM組)、女性組( TF組)及非結覈病男性組( NM組)、女性組( NF組),每組20例。所有患者入室後予靜脈輸註咪達唑崙0.1 mg/kg、芬太尼4μg/kg,靶控輸註丙泊酚1~4μg/mL,患者意識消失後採用4箇成串刺激進行肌鬆鑑測,靜脈註射順式阿麯庫銨0.15 mg/kg,噹第1箇肌顫搐反應( T1)下降至最低值併連續重複3次以上時行氣管插管,記錄起效時間、T1最大抑製程度、臨床作用時間、恢複指數、藥理作用時間及氣管插管條件和痳醉誘導前(t0)、給予肌鬆藥後5 min(t1)、15 min(t2)、30 min(t3)、45 min(t4)、1 h(t5)時的平均動脈壓和心率。結果與男性相比,T組女性起效時間較短,臨床作用時間及藥理作用時間較長( P<0.01);與N組相比,T組患者順式阿麯庫銨臨床作用時間及藥理作用時間較短,但組間差異無統計學意義( P>0.05)。結論結覈病患者順式阿麯庫銨單次靜脈註射時女性較男性更敏感,錶現為起效時間較短,臨床作用時間及藥理作用時間較長。
목적:탐토성별대결핵병환자순식아곡고안약효학삼수적영향。방법택기행전신마취수술80례,결핵병( T조)급비결핵병( N조)환자40례,량조의성별불동분위결핵병남성조( TM조)、녀성조( TF조)급비결핵병남성조( NM조)、녀성조( NF조),매조20례。소유환자입실후여정맥수주미체서륜0.1 mg/kg、분태니4μg/kg,파공수주병박분1~4μg/mL,환자의식소실후채용4개성천자격진행기송감측,정맥주사순식아곡고안0.15 mg/kg,당제1개기전휵반응( T1)하강지최저치병련속중복3차이상시행기관삽관,기록기효시간、T1최대억제정도、림상작용시간、회복지수、약리작용시간급기관삽관조건화마취유도전(t0)、급여기송약후5 min(t1)、15 min(t2)、30 min(t3)、45 min(t4)、1 h(t5)시적평균동맥압화심솔。결과여남성상비,T조녀성기효시간교단,림상작용시간급약리작용시간교장( P<0.01);여N조상비,T조환자순식아곡고안림상작용시간급약리작용시간교단,단조간차이무통계학의의( P>0.05)。결론결핵병환자순식아곡고안단차정맥주사시녀성교남성경민감,표현위기효시간교단,림상작용시간급약리작용시간교장。
Objective To investigate the pharmacodynamic parameters of cis -atracurium in tuberculosis patients with different gender .Methods Eighty patients ( ASAⅠor Ⅱ) received selective general anesthesia were enrolled in this study.They were divided into tuberculosis group (Group T, n=40) andnon -tuberculosis group (Group N, n=40), whom were subsequently subdivided into male (TM and NM) and female (TF and NF) subgroups.All patients re-ceived an intravenous injection of midazolam (0.1 mg/kg), fentanyl (4μg/kg) and propofol (with target plasma concen-tration of 1-4 μg/mL).The neuromuscular block level was measured by neuromuscular transmission monitor after pa -tients'consciousness disappeared .With an intravenous 0.15 mg/kg of cis -atracurium, the responses were defined in terms of the percentages of maximum suppression at the first contraction ( T1 ) of the train-of-four of the adductor polli-cis muscle.Endotracheal intubation was conducted when T 1 fell to its lowest and repeated no less than 3 times.The onset time, the maximum inhibition of T 1 , the clinical effect time , the recovery index , the pharmacological effect time and the endotracheal intubation conditions were recorded .MAP and HR were measured before anesthesia induction ( t0 ) , and 5 min ( t1 ) , 15 min ( t2 ) , 30 min ( t3 ) , 45 min ( t4 ) , and 1 h ( t5 ) after general anesthesia .Results The onset time of cis-atracurium in Group TF was significant shorter than that in Group TM , with significantly longer clinical effect time ( P<0.01).However, there was no significant difference between Group NM and NF (P>0.05).Compared with Group N, the clinical effect time and pharmacological effect time in Group T were significantly shorter (P<0.05), while there was no significant difference in the onset time , the maximum inhibition of T 1 , the clinical effect time , the recovery index , or the pharmacological effect time between the two groups (P>0.05).No significant difference was found in the endotrache-al intubation conditions or hemodynamics before or after induction among the four subgroups ( P>0.05 ) .Conclusion Female tuberculosis patients are more sensitive to a single intravenous injection of cis -atracurium, presenting with short-ened onset time , and lengthened clinical effect time and pharmacological effect time .